Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 7/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MMP7 | P09237 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | MMP12 | P39900 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.51 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | PTGES | O14684 | 1/20 | 0.48 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.48 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4936946 | 0.83 | SMN1; SMN2 (0.77) | BMP1SMN1; SMN2LMNAHTTNPC1 | |
| SCHEMBL17230532 | 0.83 | BMP1 (0.55) | BMP1SMN1; SMN2LMNAHTTNPC1 | |
| SCHEMBL1106906 | 0.82 | CNR2 (0.54) | BMP1SMN1; SMN2LMNAHTTNPC1 | |
| SCHEMBL13979922 | 0.81 | CNR2 (0.61) | BMP1SMN1; SMN2LMNAHTTNPC1 | |
| SCHEMBL4204765 | 0.80 | LMNA (0.76) | SMN1; SMN2LMNAHTTNPC1RAB9A | |
| SCHEMBL398044 | 0.80 | CNR2 (0.57) | SMN1; SMN2LMNAHTTNPC1RAB9A | |
| SCHEMBL9190749 | 0.80 | PKM (0.43) | BMP1MMP1MMP7MMP8MMP12 | |
| SCHEMBL10385428 | 0.79 | BMP1 (0.51) | BMP1SMN1; SMN2LMNAHTTNPC1 | |
| SCHEMBL14229338 | 0.79 | TAS2R14 (0.62) | BMP1SMN1; SMN2LMNAHTTNPC1 | |
| Hydrochloric Acid SCHEMBL29285860 | 0.79 | LMNA (0.73) | SMN1; SMN2LMNAHTTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009062036-A2 | PROCESSES FOR PREPARING LEVOCETIRIZINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | DR. REDDY'S LABORATORIES LTD. (IN) | 2009-05-14 | — | — | WO | claimed |
| EP-2167479-B1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY OPTICALLY PURE LEVOROTATORY AND DEXTROROTATORY ENANTIOMERS OF CETIRIZINE USING NOVEL INTERMEDIATES | SYMED LABS LTD (IN) | 2013-09-11 | — | — | EP | disclosed |
| WO-2012101648-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF ENANTIOMERICALLY PURE 2-METHOXY-5-[(2R)-2-(4-ALKYLPIPERAZIN-L-YL)PROPYL]-BENZENESULFONAMIDE | HAVALDAR FREDDY H | 2012-08-02 | — | — | WO | disclosed |
| US-8084606-B2 | Process for preparation of substantially optically pure levorotatory and dextrorotatory enantiomers of cetirizine using novel intermediates | SYMED LABS LIMITED (IN) | 2011-12-27 | — | — | US | disclosed |
| EP-2167479-A1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY OPTICALLY PURE LEVOROTATORY AND DEXTROROTATORY ENANTIOMERS OF CETIRIZINE USING NOVEL INTERMEDIATES | Symed Labs Limited (IN) | 2010-03-31 | — | — | EP | disclosed |
| US-20090281318-A1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY OPTICALLY PURE LEVOROTATORY AND DEXTROROTATORY ENANTIOMERS OF CETIRIZINE USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2009-11-12 | — | — | US | disclosed |
| WO-2009062036-A2 | PROCESSES FOR PREPARING LEVOCETIRIZINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | DR. REDDY'S LABORATORIES LTD. (IN) | 2009-05-14 | — | — | WO | disclosed |
| WO-2008152650-A1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY OPTICALLY PURE LEVOROTATORY AND DEXTROROTATORY ENANTIOMERS OF CETIRIZINE USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281318-A1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY OPTICALLY PURE LEVOROTATORY AND DEXTROROTATORY ENANTIOMERS OF CETIRIZINE USING NOVEL INTERMEDIATES | CYP3A5, TPH1, CYP51A1 | BMP1 4797/4885SMN1; SMN2 4443/4885LMNA 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.